Mumbai: Pharmaceutical company Cadila Healthcare said on 20 October that its parent firm Zydus Cadila has received US Food and Drug Administration approval to market Risperidone Tablets, used to treat depression.
Risperidone falls in the central nervous system (CNS) segment, Cadila Healthcare said in a filing to the Bombay Stock Exchange.
The Risperidone tablets would be available in 0.25, 05, 1, 2, 3 and 4 mg strengths, the company said.
The group now has 41 approvals and has so far filed for 79 Abbreviated New Drug Applications (ANDA), it added.
Last week, Zydus Cadila filed an Investigational New Drug application with the Drugs Controller General of India for ZYT 1, which is used to prevent heart attack and stroke.
Shares of the firm were trading at Rs253, down 2.64% in afternoon trade on the BSE.